Comedications Associated with Immune-Related Adverse Events from Immune-Checkpoint Inhibitors.

ABSTRACT: Immune-checkpoint inhibitors (ICI) have revolutionized cancer treatment but are responsible for various immune-related adverse events (irAE). The impact of non-anticancer medications (comedications) on irAE occurrence remains largely unexplored. The objective of this study was to assess comedications associated with an increased reporting of irAE with ICIs. In this pharmacovigilance study, all individual case safety reports (ICSRs) involving ICIs reported in the World Health Organization international pharmacovigilance database Vigibase up to January 2024 were extracted. All suspect or interacting comedications were analyzed individually and as drug classes using Anatomical Therapeutic Chemical classification level 4. The primary outcome was the reporting odds ratio (ROR) of irAE in patien

SUBMITTER: Laurent L 

PROVIDER: S-EPMC12355013 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature